On the morning of April 11, 2024, the clinical launch meeting of the "Additive Manufacturing Porous absorbable artificial bone" project of T-Bright  (Kunshan) Biotechnology was successfully held in the demonstration classroom of the inpatient building of the First Attached Hospital of SU University.

Yang Huilin, Director of the Department of Orthopedics of the First Affiliated Hospital of SU University, and Chen Feihao, general manager of T-Bright  (Kunshan) Biotechnology, delivered speeches respectively. Chen Jianyu, chairman of T-Bright  (Kunshan) Biotechnology, specially assisted in product introduction (product training and demonstration), and representatives of Mediastron introduced the test plan and specific test requirements.

This is a multicenter, randomized, single-blind, parallel controlled clinical trial to evaluate the efficacy and safety of the product for the treatment of bone defects in the four limbs of the human body.

The opening meeting marked that the project officially entered the stage of human clinical trials.